Notice Pursuant to the National Cooperative Research and Production Act of 1993-Customer Experience Hub, 26929-26930 [2024-07942]

Agencies

• Antitrust Division
• Department of Justice

[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Pages 26929-26930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07942]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Customer Experience Hub

    Notice is hereby given that, on January 11, 2024, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), The Customer Experience Hub 
(``CX Hub'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing (1) the 
identities of the parties to the venture and (2) the nature and 
objectives of the venture. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture as of the date of this filing are: AcademyHealth, 
Washington, DC; Access to Advanced Health Institute, Seattle, WA; 
Acclinate, Inc., Birmingham, AL; Addinex Technologies, Inc., New York, 
NY; Advanced BioScience Laboratories, Inc., Rockville, MD; Advanced 
Life Technologies LLC, Santa Barbara, CA; Advanced Silicon Group, 
Lowell, MA; Altec, Inc., Natick, MA; AmebaGone, Madison, WI; AMK 
Technologies of Ohio LLC, Mount Vernon, OH; AN2 Therapeutics, Inc., 
Menlo Park, CA; Angels for Change, Tampa, FL; Applied Research 
Associates, Albuquerque, NM; Arizona State University, Tempe, AZ; 
Aspire Clinical Intelligence LLC, Grand Forks, ND; Auburn University, 
Auburn, AL; Battelle Memorial Institute, Columbus, OH; BB Medical 
Surgical, Inc., San Francisco, CA; BCG Federal Corp., Washington, DC; 
Better Life Learning LLC, Birmingham, MI; BioAustinCTX, Austin, TX; 
BioBridge Global, San Antonio, TX; BioCircuit Technologies, Atlanta, 
GA; BioLum Sciences LLC, Dallas, TX; Biomotivate, Pittsburgh, PA; 
Biosortia Microbiomics, Dublin, OH; Bluehalo Labs LLC, Albuquerque, NM; 
Boston Children's Hospital, Boston, MA; Boston Engineering Corp., 
Waltham, MA; Boston Medical Center Corp., Boston, MA; BroadReach Group 
LLC, Washington, DC; Burnett School of Medicine at Texas Christian 
University, Fort Worth, TX; California Medical Innovations Institute, 
San Diego, CA; Cancer Prevention & Research Institute of Texas, Austin, 
TX; CarePredict, Inc., Plantation, FL; Children's National Hospital; 
Washington, DC; Children's Nebraska, Omaha, NE; ClearCam, Inc., Austin, 
TX; Cleveland Clinic, Cleveland, OH; Clinical Research Payment Network, 
Elkhart, IL; Clinical Research Strategies LLC, Wexford, PA; Cocrystal 
Pharma, Inc., Miami, FL; Cook Children's Health Care System, Fort 
Worth, TX; Creare LLC, Hanover, NH; Creatv MicroTech, Inc., Rockville, 
MD; Critical Innovations LLC, Lawndale, CA; Cure Rare Disease, Inc., 
Woodbridge, CT; Dallas College, Dallas, TX; Deloitte Consulting LLP, 
Arlington, VA; Domestic Monitoring Initiative (DMI), Erie, PA; Durahip 
LLC, San Antonio, TX; Eagle Health Analytics LLC, San Antonio, TX; 
Egality Sciences LLC, Houston, TX; Eisana, The Woodlands, TX; Elcomm, 
Kennesaw, GA; Emory University, Atlanta, GA; emTruth, Glendale, CA; 
Fempower Health, Irvington, NY; First Choice Professionals dba First 
Health Advisory,

[[Page 26930]]

Scottdale, AZ; Florida Institute for Human & Machine Cognition, Inc., 
Pensacola, FL; GaitIQ, Inc., San Antonio, TX; GelSana Therapeutics, 
Inc., Aurora, CO; GeneInfoSec, Boulder, CO; Gener8 LLC, San Jose, CA; 
Georgetown University, Washington, DC; Ginkgo Bioworks, Inc., Boston, 
MA; Glendor, Inc., Draper, UT; Grant Halliburton Foundation, Inc., 
Dallas, TX; Gwen Lily Research Foundation, Irving, TX; Harmony 
Healthcare Solutions, Inc. dba Harmony Health, Sunnyvale, CA; 
Healthpointe Solutions, Inc., Austin, TX; HERMTAC LLC, Dallas, TX; ICON 
Government and Public Health Solutions, Inc., Blue Bell, PA; Inhance 
Digital Corp., Los Angeles, CA; Innovation Incubator, Inc., Bayside, 
NY; International Business Machines Corp., Armonk, NY; INVIZA Corp., 
Malden, MA; IOTAI, Inc., Fremont, CA; Irrational Labs, Oakland, CA; 
Irving Burton Associates, Silver Springs, MD; JPS Health Network, Fort 
Worth, TX; Jubilant Hollisterstier LLC, Spokane, WA; Jurata Thin Film, 
Inc., Chapel Hill, NC; K2 Biolabs, Inc., Houston, TX; Kaibab Health, 
Sheridan, WY; Knight Technical Solutions LLC, Huntsville, AL; Lazarus 
3D, Philomath, OR; Lighthouse XR LLC, Chester, VA; Limax Biosciences, 
Inc., Somerville, MA; Locus Biosciences, Morrisville, NC; LSU Health 
Science Center: New Orleans, New Orleans, LA; LSU Health Shreveport, 
Shreveport, LA; Luna Labs USA LLC, Charlottesville, VA; M3D, Inc., Ann 
Arbor, MI; MapHabit, Inc., Atlanta, GA; Maravai Lifesciences, San 
Diego, CA; Maryland Technology Development Corp., Columbia, MD; Mass 
General Brigham, Somerville, MA; Maxwell Biosciences, Inc., Austin, TX; 
MDC Studio, Inc., Baltimore, MD; Medable, Palo Alto, CA; MedVector, El 
Segundo, CA; Memsel, Inc., Fort Worth, TX; Moberg Analytics, Inc., 
Philadelphia, PA; Molecular Technologies Laboratories LLC, Columbus, 
OH; MRIGlobal, Gaithersburg, MD; National Association of Community 
Health Centers, Inc., Bethesda, MD; National Hispanic Health 
Foundation, Washington, DC; National Resilience, Inc., San Diego, CA; 
National Strategic Research Institute, Omaha, NE; Neurxstem, Inc., 
Columbus, OH; New Horizons Diagnostics Corp., Baltimore, MD; NIRSense, 
Inc., Richmond, VA; North Carolina State University, Raleigh, NC; 
NXTech, Inc., Patchogue, NY; O3 World LLC, Philadelphia, PA; Oceanit 
Laboratories, Inc., Honolulu, HI; OLSF Ventures, Tulsa, OK; Oregon 
Bioscience Association, Portland, OR; Orlando Health, Orlando, FL; 
Otter Cove Solutions LLC, Gaithersburg, MD; OXOS Medical, Atlanta, GA; 
Parkland Center for Clinical Innovation, Dallas, TX; Parkland Health, 
Dallas, TX; Patchwise Labs, Alameda, CA; Pennington Biomedical Research 
Center, Baton Rouge, LA; Pennsylvania State University--College of 
Medicine, Hershey, PA; Phronetik, Inc., Flower Mound, TX; Polaris 
Sensor Technologies, Inc., Huntsville, AL; PPD Development LP, 
Wilmington, NC; ppxTEX LLC, Jackson, MS; PragmaClin, St. John's, 
CANADA; PriMetaz, Boston, MA; Proteios Technology, Inc., Issaquah, WA; 
Purdue University, West Lafayette, IN; Qana Therapeutics, Inc., Austin, 
TX; QuantaSpec, Inc., Essex Junction, VT; Re:Build Manufacturing, 
Framingham, MA; Research Your Health LLC, Plano, TX; Resonantia 
Diagnostics, Inc., Dallas, TX; Ridgeline Therapeutics, Houston, TX; 
Ronawk, Inc., Overland Park, KS; Rubitection, Pittsburgh, PA; Rubix LS, 
Lawrence, MA; Rutgers University, New Brunswick, NJ; Safebeat Rx, Inc., 
Carson, CA; SafeGuard Surgical, Tampa, FL; SafetySpect, Inc., Grand 
Forks, ND; Safi Biotherapeutics, Inc., Cambridge, MA; SanaHeal, Inc., 
Boston, MA; Scorpius BioManufacturing, San Antonio, TX; Signature 
Science LLC, Austin, TX; Signum Technologies, Inc., Randor, PA; SimX, 
Inc., San Francisco, CA; Sonera Magentics, Inc., Berkeley, CA; 
Southwest Research Institute, San Antonio, TX; Southwest Texas Regional 
Advisory Council, San Antonio, TX; Sozo Dx LLC, Plano, TX; Sparta 
Science, San Francisco, CA; SPEAR Human Performance, Inc., Tallahassee, 
FL; Spectral Platforms, Duarte, CA; Sperry Medtech, Inc., Springfield, 
MA; Stanford Byers Center for Biodesign, Stanford, CA; Stellarray, 
Inc., Austin, TX; Swaza, Mountain View, CA; Talis Biomedical Corp., 
Redwood City, CA; Texas A&M Engineering Experiment Station, Bryan, TX; 
Texas Biomedical Research Institute, San Antonio, TX; Texas Healthcare 
and Bioscience Institute, Austin, TX; Texas Oncology, Dallas, TX; Texas 
State University--Translational Health Research Center, San Marcos, TX; 
Texas Tech University Health Sciences Center, Lubbock, TX; Texas 
Woman's University, Denton, TX; The Geneva Foundation, Tacoma, WA; The 
Henry M. Jackson Foundation for the Advancement of Military Medicine, 
Bethesda, MD; The Life Raft Group, Wayne, NJ; The Nebraska Medical 
Center, Omaha, NE; The University of Texas at Dallas, Richardson, TX; 
The University of Texas: M.D Anderson Cancer Center, Houston, TX; 
TheraTec, Inc., Horace, ND; TheraVista Health, Brentwood, TN; Thomas 
Jefferson University, Philadelphia, PA; Tranexamic Technologies LLC, 
Dallas, TX; Ubiros, Inc., Natick, MA; University City Science Center, 
Philadelphia, PA; University of California at Riverside, Riverside, CA; 
University of Delaware, Newark, DE; University of Hawai'i System, 
Honolulu, HI; University of Montana, Missoula, MT; University of 
Nebraska Medical Center, Omaha, NE; University of Notre Dame, Notre 
Dame, IN; University of Southern California, Los Angeles, CA; 
University of Texas at Austin, Austin, TX; University of Texas at San 
Antonio, San Antonio, TX; Univox Technical Solutions LLC dba Univox 
LLC, Tijeras, NM; Vanderbilt University, Nashville, TN; Varda Space 
Industries, Inc., El Segundo, CA; VelocityTX, San Antonio, TX; Verily 
Life Sciences LLC, South San Francisco, CA; ViBo Health, Fairfax, VA; 
Vivonics, Inc., Bedford, MA; Wake Forest University Health Sciences, 
Winston Salem, MA; Weinberg Medical Physics, Inc., Rockville, MD; West-
Tech Materials, Keller, TX; Yuzu Labs Public Benefit Corp., San 
Francisco, CA; Zeteo Biomedical LLC, Austin, TX; Zeteo Tech, Inc., 
Sykesville, MD; Zymeron Corp., Durham, NC.
    Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the CX Hub is 
a new consortium created in response to requirements of the Advanced 
Research Projects Agency for Health (ARPA-H) for the active transition 
of health innovation in an expedient, safe, cost-effective, accessible, 
and sustainable manner that reaches all Americans. The CX Hub will take 
a human-centered approach to develop technologies and health solutions 
that will be accessible, desirable, and affordable for all. It will 
also take a proactive approach to enhance clinical trials, reach 
representative patient populations, and capture outcomes data for 
future use leading to better and more equitable health outcomes for 
all.

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07942 Filed 4-15-24; 8:45 am]
BILLING CODE P